Engrail Therapeutics is a precision neuroscience biotechnology company focusing on a new direction to reduce the diseases that impact the nervous system. The company concentrates on targeting specific molecular pathways and cellular mechanisms underlying neurological conditions. This precision-based strategy not only enhances efficacy but also minimizes side effects, thus offering patients a more tailored and sustainable treatment option.
Engrail Therapeutics has raised $157 million in a Series B funding round. The new round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners. Moreover, it had participation from Eight Roads Ventures, RiverVest Venture Partners, Red Tree Venture Capital, funds managed by Abrdn Inc., Ysios Capital, Longwood Fund, and existing founding investor Pivotal Life Sciences. In total, Engrail Therapeutics has raised more than $220 million till that moment.
Engrail Therapeutics, San Diego, California, United States, was founded in 2019 by
Stephen Cunningham and Vikram Sudarsan. “With strong financial backing from highly sophisticated and dedicated life science investors, we are well-positioned to deliver multiple value-creating milestones. We look forward to completing our ongoing ENX-102 phase 2 study in generalised anxiety disorder and advancing the rest of our pipeline into clinical development,” said Vikram Sudarsan, President and CEO of Engrail Therapeutics.
